Mandate is valid until March 2018 due to the resignation request of Victor Mezei

FERNANDO ALMEIDA IS ELECTED PRESIDENT OF THE DIRECTOR COUNCIL OF INTERFARMA

Home page > Notícias > FERNANDO ALMEIDA IS...

Edit email address
Invalid email
Email Sent
Date: 26/06/2017


The executive Fernando Almeida, general manager of Chiesi, was unanimously elected the new president of the Director Council of INTERFARMA, in an extraordinary meeting held this Monday morning, 19, with 100% of Council attendance.

 

Fernando takes on Victor Mezei position, who asked for resignation of his role in INTERFARMA.

“It is an excellent choice to keep the management going”, said Mezei, who indicated Almeida to replace him.

 

Also unanimously, José Antônio Vieira, Novartis general manager, took on the Council vice presidency.

 

Almeida is graduated in business administration with MBA in General Management at INSPER of São Paulo. Chiesi general manager since January 2013, the new Council president began his career at Janssen-Cilag, also working at AstraZeneca and Roche.

 

Overall, he sums 29 years of experience in the pharmaceutical market, working on several positions and leading different projects. Since April 2016, Almeida was substitute vice president of INTERFARMA Management Committee.

 

“I am very pleased for the confidence and the indication I receive from Victor Mezei. And also for the support of Antônio Britto, INTERFARMA executive president, and all the counselors. Surely, there is a continuity project as I already am in the Management Committee. As I have always done during these years at INTERFARMA, my goal is to collaborate with the entity’s projects, with the opportunities we have and help Britto on managing the entity”.

About INTERFARMA

Founded in 1990, INTERFARMA currently has 54 associated companies. Today, these labs are responsible for sales, in the pharmacy channel, of 82% of the market reference medicines and also for 33% of the generic ones produced by companies that started to be controlled by the associated labs. Also, the associated companies are responsible for 46% of the production of medicine exempted from prescription (MIBs) of the Brazilian market and for 52% of the prescription drugs (50% out of the retail market total).